-

Life Sciences Entrepreneur John Flavin launches Portal Innovations

Partners with Trammell Crow Company to provide start-up lab space

CHICAGO--(BUSINESS WIRE)--Portal Innovations, LLC today announced they are launching a new platform to seed and accelerate life sciences, medtech and bioinformatics ventures. The company is the brainchild of John Flavin, a seasoned life sciences executive and entrepreneur with over 25 years of industry experience in finance, operations and innovation. In addition to providing management expertise, team assembly and other start-up resources, Portal is partnering with Trammell Crow Company, a leading real estate developer in the United States, to design and develop wet and dry lab space to support a carefully curated portfolio of early stage companies in the recently announced Fulton Labs complex in Fulton Market.

“There is an increasing pipeline of talent and biomedical innovation emerging from Midwest universities and companies that have the potential to be novel products in the healthcare market. However, entrepreneurs need an ecosystem of strong business and science teams coupled with capital and lab space to move the innovation from proof of concept to commercialization,” said Raju Prasad Ph.D., Senior Biotechnology Equity Research Analyst at William Blair. “Portal is well positioned to successfully address this opportunity.”

Aware of this emerging opportunity in the Midwest, John Flavin created Portal Innovations to seed, build and scale early stage ventures emerging from academic laboratories, companies and innovation hubs.

“The nexus of talent, world-class universities, innovative companies and business incubators here in Illinois make up an entire ecosystem of opportunities that rivals any state in the nation,” said Governor JB Pritzker. “My administration’s five-year blueprint for Illinois’ economy identified life sciences as a key sector that would drive our state’s growth, and I’m excited to see Portal Innovations set up shop in Illinois and build a groundbreaking venture that will keep our state at the forefront of innovation.”

“John’s endeavor is so timely given that Illinois Universities have garnered more than $1 Billion in NIH funding annually for biomedical innovation setting the stage to commercialize more of this breakthrough science,” said Brad Henderson, CEO of P33 Chicago, a private sector led initiative driving global technology leadership for Chicago. “As a region, we’re developing a robust ecosystem with a strong bench of assets and innovators in the life sciences sector – a critical first step in our ability to translate these assets into industry-led commercial viability. ”

To Portal, John brings a strong track record of successful life sciences and medtech senior management experience and innovation expertise in both the start-up and established company setting. Most recently John served as Chief Financial Officer at Endotronix and helped them secure $70 million to fund their pivotal clinical program. In parallel, he cofounded Pyxis Oncology as founding chairman and helped the team raise a $22 million Series A round to launch its novel immuno-oncology antibody drug platform. Over his career, he has co-founded and scaled several life sciences companies as President and CFO including Advanced Life Sciences and MediChem Life Sciences and has also co-founded and led transformative life sciences incubators including MATTER and the Polsky Center for Entrepreneurship and Innovation at the University of Chicago. John has successfully raised over $345 million of public, private and philanthropic capital including 2 NASDAQ IPOs to fund the development of these impactful organizations.

“John is a prolific company builder. We’re grateful for his contributions over the last 2 years at Endotronix, which include securing our Series D financing and building a strong finance, legal, and accounting leadership team. His efforts have positioned us well to execute our clinical program and move to the next phase,” said Harry Rowland, co-founder and CEO of Endotronix.

About Portal Innovations, LLC

Portal Innovations is building a life sciences, medtech and bioinformatics start-up platform based in Chicago, Illinois. It is bringing together high-performing entrepreneurial teams, global capital and industry partners to accelerate biomedical innovations from discovery through commercial proof of concept. Portal is partnering with Trammell Crow Company to provide state-of-the art shared wet and dry labs for life sciences, medtech and bioinformatics companies. Learn more at www.portalinno.com.

Contacts

John Flavin
Founder & CEO, Portal Innovations, LLC
Phone: 630.297.1600
Email: john.flavin@portalinno.com

Portal Innovations, LLC


Release Versions

Contacts

John Flavin
Founder & CEO, Portal Innovations, LLC
Phone: 630.297.1600
Email: john.flavin@portalinno.com

More News From Portal Innovations, LLC

Portal Innovations Expands Powered by Portal Model to Broaden Access to Scientific Innovators

PROVIDENCE, R.I.--(BUSINESS WIRE)--Portal Innovations today announced plans to scale its Powered by Portal managed services platform, deepening partnerships with universities, economic development organizations, and government stakeholders to provide end-to-end expertise in lab operations, venture support and investing, helping entrepreneurs in emerging markets move faster. As part of this expansion, Portal is opening Ocean State Labs, marking its second Powered by Portal location following the...

Portal Atlanta at Science Square Grows to Over 30 Member Companies, Marking Major Milestone 15 Months After Launch

ATLANTA--(BUSINESS WIRE)--Portal Innovations announced continued growth at Portal Atlanta at Science Square, with the addition of seven new member companies, bringing the total ecosystem to 32 biotech, medtech, digital health, and cleantech, organizations served, just 15 months after launch. The milestone – which includes 7 new members in just the month of January 2026 alone – highlights the rapid momentum building around Science Square and Atlanta’s expanding life sciences and medtech communit...

ClostraBio, Inc. Obtains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™

CHICAGO--(BUSINESS WIRE)--ClostraBio, Inc., a biotech company pioneering microbiome-based solutions for gastrointestinal health, today announced that its unique, next-generation probiotic strain, Anaerostipes caccae CLB101™, has been granted self-affirmed GRAS (Generally Recognized as Safe) status by a panel of scientific experts. This milestone clears the path for CLB101™ to enter the U.S. market as the first and only commercially available strain of Anaerostipes caccae. A strict anaerobe isol...
Back to Newsroom